Epoprostenol sodium
Based on 1 publication(s) in Google Scholar
Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.03%
- CAS 番号: 61849-14-7
- 分子式: C20H31NaO5
- 分子量:374.45
-
保管条件:
-20°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-A0096
IloprostPGI2 Analogue -
HY-14870
SelexipagProstaglandin Receptor Agonist -
HY-128868G
FITC-Dextran (MW 150000)Fluorescent Dyes -
HY-108719
Insulin glargineInsulin Analog -
HY-108566
U-46619TXA2 Agonist -
HY-108415
Cloprostenol sodium saltProstaglandin Receptor Agonist -
HY-18966
PF-04418948EP2 Receptor Antagonist -
HY-108559
L-161982EP4 Receptor Antagonist -
HY-15274
L-798106EP3 Receptor Antagonist -
HY-16963
GW627368Prostaglandin Receptor Antagonist -
HY-108562
SC-51322EP1 Antagonist -
HY-102065
SC-19220EP1 Antagonist
MedChemExpress（MCE）の使用を引用している文献 Epoprostenol sodium
More
Customer Validation & Images
-
Cell Imaging/Staining
Endogenous Metabolite アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
|
Human Endogenous Metabolite |
体外実験
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 61849-14-7
-
性状 Solid
-
分子量 374.45
-
分子式 C20H31NaO5
-
Color White to yellow
-
SMILES
CCCCC[C@H](O)/C=C/[C@@H]1[C@@]([C@]2([H])C[C@H]1O)([H])C/C(O2)=C/CCCC(O[Na])=O
-
別名
Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 Oct 2;16(1):8779. PMID: 41038808
Epoprostenol sodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Oct 2;16(1):8779. [Abstract]
Transmission electron microscopy and quantitative analysis of platelet morphology and platelet-derived microparticles in washed platelets isolated using Epoprostenol sodium (0.1 μg/mL; including a 10-min centrifugation step during platelet Obtain) in nMG, HC, and MMS groups.
溶剤 & 溶解度
体外:
H2O : 25 mg/mL (66.76 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
プロトコル
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
純度とドキュメンテーション
-
データシート (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Provencher S, et al.Quality of life, safety and efficacy profile of thermostable flolan in pulmonary arterialhypertension. PLoS One. 2015 Mar 20;10(3):e0120657. [Content Brief]
[2]. Lambert O, et al. Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted[J]. Drug Design, Development and Therapy, 2012: 61-70. [Content Brief]
[3]. Akagi S, et al. Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension[J]. International journal of cardiology, 2013, 165(3): 499-505. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.6706 mL | 13.3529 mL | 26.7058 mL | 66.7646 mL |
| 5 mM | 0.5341 mL | 2.6706 mL | 5.3412 mL | 13.3529 mL | |
| 10 mM | 0.2671 mL | 1.3353 mL | 2.6706 mL | 6.6765 mL | |
| 15 mM | 0.1780 mL | 0.8902 mL | 1.7804 mL | 4.4510 mL | |
| 20 mM | 0.1335 mL | 0.6676 mL | 1.3353 mL | 3.3382 mL | |
| 25 mM | 0.1068 mL | 0.5341 mL | 1.0682 mL | 2.6706 mL | |
| 30 mM | 0.0890 mL | 0.4451 mL | 0.8902 mL | 2.2255 mL | |
| 40 mM | 0.0668 mL | 0.3338 mL | 0.6676 mL | 1.6691 mL | |
| 50 mM | 0.0534 mL | 0.2671 mL | 0.5341 mL | 1.3353 mL | |
| 60 mM | 0.0445 mL | 0.2225 mL | 0.4451 mL | 1.1127 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Epoprostenol sodium 関連分類
HY-A0126A 関連分類
Powered by Bioz